Mar 15, 2024 8:00am EDT Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
Mar 11, 2024 7:30am EDT Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
Mar 05, 2024 8:01am EST Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Mar 04, 2024 8:01am EST Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
Feb 15, 2024 8:01am EST Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Jan 17, 2024 7:30am EST Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
Nov 30, 2023 8:00am EST FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Nov 08, 2023 4:01pm EST Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
Nov 01, 2023 8:00am EDT Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
Oct 10, 2023 8:00am EDT Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
